Exciting news for the atopic dermatitis community!
ESC is excited to share that two new treatments for atopic dermatitis – Rinvoq® (upadacitinib) and Adtralza® (tralokinumab) – have been approved by Health Canada.
Rinvoq® (upadacitinib) is an oral, once-daily selective JAK inhibitor for the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis (AD) who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable.
Adtralza® (tralokinumab) a subcutaneous injection for the treatment of moderate-to-severe atopic dermatitis (AD) in adults aged 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
ESC’s Executive Director Amanda Cresswell-Melville shares; ” Atopic dermatitis can be very burdensome and can impact patient and caregiver quality-of-life. Its impacts are often underestimated and misunderstood. Patients may be seeking additional options to address their unmet needs in the management of their condition, and these new treatment options bring hope to these patients.”
While the Heath Canada approval is an early step in these new treatments being made available to patients, it’s an exciting step forward to the atopic dermatitis community.
Canadians suffering with eczema and/or atopic dermatitis should direct any specific questions they may have about their condition or treatment plan, to their own qualified health care professional.